Loading...
You are here:  Home  >  News  >  Business  >  Current Article

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

By   /  September 20, 2021  /  Comments Off on ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

    Print       Email


ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

  • Phase 3 trial met its primary and key secondary endpoints
  • Libtayo is one of two PD-(L)1 inhibitors to demonstrate positive Phase 3 results in first-line advanced NSCLC irrespective of histology both as monotherapy and in combination with chemotherapy
  • Trial enrolled patients with varied baseline characteristics, including squamous and non-squamous histologies and all PD-L1 expression levels; 84% had an ECOG 1 performance status (reduced daily functioning)

PARIS and TARRYTOWN, N.Y. September 19, 2021 – Positive Phase 3 results for Sanofi and…



See original article

    Print       Email

You might also like...

TSMC Recognizes Partners of the Year at 2021 OIP Ecosystem Forum

Read More →